Investigational drug · Phase 3
SHR-1819
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
4 still active
All registered trials
13
Any phase or sponsor naming "SHR-1819"
First trial start
2023
Sep 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1819", any sponsor or status.
Conditions studied
As listed on its trial records.
- Seasonal Allergic Rhinitis
- Moderate to Severe Atopic Dermatitis
- Moderate-to-severe Atopic Dermatitis
- Adolescents With Moderate-to-severe Atopic Dermatitis
- Prurigo Nodularis
- Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Allergies (allergic rhinitis) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1819" as an intervention, largest first.
- Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06468956 · 652 participants · Start Jun 14, 2024 · Primary completion Aug 26, 2026
Drug: SHR-1819; Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Shanghai, China
- Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo NodularisPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06554509 · 423 participants (planned) · Start Sep 19, 2024 · Primary completion Oct 2028
Drug: SHR-1819 Injection; SHR-1819 Injection Placebo · For: Prurigo Nodularis
Sites: Beijing, China
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisPivotal-lookingActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07688772 · 220 participants · Start Aug 11, 2026 · Primary completion Dec 2026
Drug: SHR-1819 Injection; SHR-1819 Injection Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
- A Study of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07309055 · 201 participants (planned) · Start Mar 21, 2026 · Primary completion Nov 2027
Drug: SHR-1819 Injection; SHR-1819 Injection Placebo · For: Adolescents With Moderate-to-severe Atopic Dermatitis
Sites: Shenyang, China; Shanghai, China
- A Study of SHR-1819 in Patients With Moderate-to-severe Atopic DermatitisPivotal-lookingActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07321951 · 201 participants · Start Jan 9, 2026 · Primary completion Jun 2027
Drug: SHR-1819 Injection; SHR-1819 Injection Blank Preparation · For: Moderate-to-severe Atopic Dermatitis
Sites: Guangzhou, China; Hangzhou, China
- A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy SubjectsPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07264335 · 160 participants · Start Mar 7, 2026 · Primary completion Jun 26, 2026
Drug: SHR-1819 Injection · For: Atopic Dermatitis
Sites: Hefei, China
- Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisPivotal-lookingCompleted
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05549947 · 158 participants · Start Oct 8, 2022 · Primary completion Sep 15, 2023
Drug: SHR-1819; Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Shanghai, China
- A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07091357 · 108 participants · Start Aug 6, 2025 · Primary completion Dec 1, 2025
Drug: SHR-1819 Injection; SHR-1819 Injection Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06012812 · 79 participants · Start Sep 6, 2023 · Primary completion Jun 5, 2025
Drug: SHR-1819 injection · For: Moderate to Severe Atopic Dermatitis
Sites: Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT04772365 · 52 participants · Start Mar 1, 2021 · Primary completion Dec 10, 2021
Drug: SHR-1819; Placebo · For: Asthma
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.
Gu C, Yin H, Yang B, et al. · BMC Med 2026
- Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases.
Zhao G, Wang Z, Zhang J, et al. · J Inflamm Res 2024
- Safety, pharmacokinetics, and pharmacodynamics of anti-IL-4Rα antibody SHR-1819 in healthy subjects: A randomized, controlled phase I study.
Li N, Shakib S, Qian W, et al. · Clin Transl Sci 2024
Also in development for Seasonal Allergic Rhinitis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- MG-K10 Humanized Monoclonal AntibodyPhase 34 trials
Shanghai Mabgeek Biotech.Co.Ltd · Atopic Dermatitis, Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU)
- TQH2722Phase 33 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Seasonal Allergic Rhinitis, Atopic Dermatitis
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- TQC2938Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Seasonal Allergic Rhinitis
- JT002Phase 21 trial
Shanghai JunTop Biosciences Co., LTD · Seasonal Allergic Rhinitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.